JP6498599B2 - 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質 - Google Patents

特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質 Download PDF

Info

Publication number
JP6498599B2
JP6498599B2 JP2015509201A JP2015509201A JP6498599B2 JP 6498599 B2 JP6498599 B2 JP 6498599B2 JP 2015509201 A JP2015509201 A JP 2015509201A JP 2015509201 A JP2015509201 A JP 2015509201A JP 6498599 B2 JP6498599 B2 JP 6498599B2
Authority
JP
Japan
Prior art keywords
eev
heavy chain
library
immunoglobulin
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015509201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514811A (ja
JP2015514811A5 (enExample
Inventor
アーネスト エス． スミス
アーネスト エス． スミス
トレイシー パンディーナ
トレイシー パンディーナ
レスリー エイ． クロイ
レスリー エイ． クロイ
マーク パリス
マーク パリス
モーリス ツァオデラー
モーリス ツァオデラー
アンゲリカ モクサ
アンゲリカ モクサ
レネ カーク
レネ カーク
Original Assignee
バクシネックス インコーポレーティッド
バクシネックス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクシネックス インコーポレーティッド, バクシネックス インコーポレーティッド filed Critical バクシネックス インコーポレーティッド
Publication of JP2015514811A publication Critical patent/JP2015514811A/ja
Publication of JP2015514811A5 publication Critical patent/JP2015514811A5/ja
Application granted granted Critical
Publication of JP6498599B2 publication Critical patent/JP6498599B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015509201A 2012-04-26 2013-04-26 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質 Active JP6498599B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261639046P 2012-04-26 2012-04-26
US61/639,046 2012-04-26
US201261732776P 2012-12-03 2012-12-03
US61/732,776 2012-12-03
US13/844,388 US9708601B2 (en) 2012-04-26 2013-03-15 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US13/844,388 2013-03-15
PCT/US2013/038497 WO2013163602A1 (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018206485A Division JP2019055956A (ja) 2012-04-26 2018-11-01 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質

Publications (3)

Publication Number Publication Date
JP2015514811A JP2015514811A (ja) 2015-05-21
JP2015514811A5 JP2015514811A5 (enExample) 2016-06-16
JP6498599B2 true JP6498599B2 (ja) 2019-04-10

Family

ID=49477810

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015509201A Active JP6498599B2 (ja) 2012-04-26 2013-04-26 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質
JP2018206485A Withdrawn JP2019055956A (ja) 2012-04-26 2018-11-01 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018206485A Withdrawn JP2019055956A (ja) 2012-04-26 2018-11-01 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質

Country Status (16)

Country Link
US (3) US9708601B2 (enExample)
EP (1) EP2841606B1 (enExample)
JP (2) JP6498599B2 (enExample)
KR (1) KR102108589B1 (enExample)
CN (1) CN104520444B (enExample)
AU (1) AU2013251371B2 (enExample)
CA (1) CA2871597C (enExample)
DK (1) DK2841606T3 (enExample)
EA (1) EA028164B1 (enExample)
ES (1) ES2725673T3 (enExample)
IL (1) IL235323B (enExample)
NZ (1) NZ630854A (enExample)
PL (1) PL2841606T3 (enExample)
PT (1) PT2841606T (enExample)
SG (1) SG11201406974YA (enExample)
WO (1) WO2013163602A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2427212T3 (enExample) 2009-05-08 2018-01-20
CN104168956A (zh) 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
CA2939572A1 (en) * 2014-02-19 2015-08-27 Jody Berry Marburg monoclonal antibodies
KR20170019080A (ko) 2015-08-11 2017-02-21 주식회사 엘티전자 플렉시블 사이니지 장치
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
BR112018071686A2 (pt) * 2016-04-22 2019-02-19 Vaccinex, Inc. exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
CN110636858B (zh) 2017-05-05 2024-03-19 瓦西尼斯公司 人抗脑信号蛋白4d抗体
AU2021267163B2 (en) 2020-05-06 2024-05-23 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
IL317110A (en) 2022-06-10 2025-01-01 Vaccinex Inc Methods for selecting antibodies specific for complex membrane antigens
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
EP0758397B1 (en) 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
US7067251B2 (en) 2000-03-28 2006-06-27 University Of Rochester Methods of directly selecting cells expressing inserts of interest
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
AU2001297872B2 (en) * 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002255495A1 (en) 2001-02-02 2002-08-19 University Of Rochester Methods of identifying regulator molecules
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
JP5042631B2 (ja) 2003-12-04 2012-10-03 バクシネックス インコーポレーティッド アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7858599B2 (en) 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
EP2112930B1 (en) 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
EP2237792B1 (en) 2007-12-26 2017-05-24 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
WO2010044919A2 (en) * 2008-05-28 2010-04-22 Vgx Pharmaceuticals, Inc. Smallpox dna vaccine and the antigens therein that elicit an immune response
US20100081575A1 (en) 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
KR20110137290A (ko) 2009-01-08 2011-12-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
NO2427212T3 (enExample) 2009-05-08 2018-01-20
RS66008B1 (sr) * 2010-03-10 2024-10-31 Genmab As Monoklonska antitela protiv c-met
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AU2011248083B2 (en) * 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
SG185487A1 (en) * 2010-05-11 2012-12-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
US8834883B2 (en) 2010-06-14 2014-09-16 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2804399A1 (en) * 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
US20130164325A1 (en) 2010-07-07 2013-06-27 Albert Einstein College Of Medicine Of Yeshiva University Ceramide-like glycolipid-associated bacterial vaccines and uses thereof
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
US9447191B2 (en) 2011-05-13 2016-09-20 National University Corporation Tokyo Medical And Dental University Osteogenesis promoter
CN104168956A (zh) 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
IN2014DN08199A (enExample) 2012-03-02 2015-05-01 Vaccinex Inc
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP2951204B1 (en) 2013-01-31 2019-05-22 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
BR112018071686A2 (pt) 2016-04-22 2019-02-19 Vaccinex, Inc. exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
WO2018156509A1 (en) 2017-02-22 2018-08-30 Vaccinex, Inc. Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
DK3600419T5 (en) 2017-03-20 2024-05-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
CN110636858B (zh) 2017-05-05 2024-03-19 瓦西尼斯公司 人抗脑信号蛋白4d抗体

Also Published As

Publication number Publication date
CA2871597A1 (en) 2013-10-31
AU2013251371B2 (en) 2018-01-04
JP2015514811A (ja) 2015-05-21
CA2871597C (en) 2021-04-20
PT2841606T (pt) 2019-05-17
US20170306318A1 (en) 2017-10-26
US9708601B2 (en) 2017-07-18
EP2841606A4 (en) 2015-12-30
SG11201406974YA (en) 2014-11-27
US20130288927A1 (en) 2013-10-31
US9701958B2 (en) 2017-07-11
EA201491965A1 (ru) 2015-03-31
JP2019055956A (ja) 2019-04-11
NZ630854A (en) 2017-03-31
PL2841606T3 (pl) 2019-07-31
KR20150009560A (ko) 2015-01-26
IL235323B (en) 2020-01-30
CN104520444B (zh) 2017-12-12
ES2725673T3 (es) 2019-09-26
IL235323A0 (en) 2014-12-31
EA028164B1 (ru) 2017-10-31
KR102108589B1 (ko) 2020-05-07
CN104520444A (zh) 2015-04-15
DK2841606T3 (da) 2019-05-06
EP2841606A1 (en) 2015-03-04
AU2013251371A1 (en) 2014-11-13
US20160152971A1 (en) 2016-06-02
WO2013163602A1 (en) 2013-10-31
US10662422B2 (en) 2020-05-26
EP2841606B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
JP6498599B2 (ja) 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質
JP7072521B2 (ja) ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示
JP6043431B2 (ja) 特異的な結合タンパク質または機能性タンパク質の遺伝子転位を利用した同定
JP5804521B2 (ja) コレクション及びその使用方法
RU2625033C2 (ru) Система индикации на основе полноразмерного антитела для эукариотических клеток и ее применение
JP7470817B2 (ja) ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示
RU2747557C2 (ru) Улучшенные способы получения библиотек полинуклеотидов в вирусах осповакцины/эукариотических клетках
EP2089430A1 (en) Selection of human monoclonal antibodies by mammalian cell display
JP7085992B2 (ja) 共通軽鎖を有するトランスジェニックウサギ
US20220333130A1 (en) Episomal expression, genomic integrated lentiviral vector expression and mRNA expression of Potent Immunoglobulins Including Dimeric Immunoglobulin A1 and A2 via a furin cleavage site and 2A self-processing peptide to Enable Mucosal and Hematological Based Immunity or Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses.
US20240093177A1 (en) Methods to select antibodies specific to complex membrane antigens
RU2847466C1 (ru) Дисплей интегральных мембранных белков на поксвирусных внеклеточных вирионах в оболочке
US20250115898A1 (en) Systems and methods for simultaneous detection of antigens and ligands thereof
WO2024067759A1 (zh) 一种能够结合cldn18.2的抗体或其抗原结合片段及其应用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181212

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190313

R150 Certificate of patent or registration of utility model

Ref document number: 6498599

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250